Back to results
US 9,066,927 B2Granted
Methods of treatment using rage fusion proteins
AssigneeGalactica Pharmaceuticals, Inc.
InventorsGregory T. Bleck, David M. Hilbert
Life of this patent
Estimating the term…
Abstract
The present invention provides novel therapeutics and methods of treatment for diseases associated with activation of the advanced glycatioπ endproducts receptor (RAGE).
Claims20
A method of treating an AGE-mediated disease, comprising:
- administering to a mammal having an AGE-mediated disease a therapeutically effective amount of a pharmaceutical composition comprising an isolated fusion protein and a pharmaceutically acceptable carrier,
- wherein the fusion protein comprises at least one polypeptide comprising:
- (a) a first amino acid sequence comprising an amino acid sequence selected from the group consisting of amino acids 1-301, amino acids 24-301, amino acids 1-344, or amino acids 24-344 of SEQ ID NO:6;
- and
- (b) a second amino acid sequence at least 95% identical to a human heavy chain immunoglobulin IgG4 constant domain or a fragment thereof.
2 more elements
A method of lowering the levels of ligand bound by RAGE in a mammal in need thereof which comprises administering to the mammal a RAGE ligand-lowering amount of a fusion protein,
- wherein the fusion protein comprises at least one polypeptide comprising:
- (a) a first amino acid sequence comprising an amino acid sequence selected from the group consisting of amino acids 1-301, amino acids 24-301, amino acids 1-344, or amino acids 24-344 of SEQ ID NO:6;
- and
- (b) a second amino acid sequence at least 95% identical to a human heavy chain immunoglobulin IgG4 constant domain or a fragment thereof.
1 more element
Dependencies are inferred from the claim text.